Atheroprotective role of C5ar2 deficiency in apolipoprotein E-deficient mice

Summary

Atherogenic processes and vascular remodelling after arterial injury are controlled and driven by a plethora of factors amongst which the activation of the complement system is pivotal. Recently, we reported a clear correlation between high expressions of the second receptor for complement anaphylatoxin C5a, the C5a receptor-like 2 (C5L2, C5aR2), with high pro-inflammatory cytokine expression in advanced human atherosclerotic plaques. This prompted us to speculate that C5aR2 might have a functional role in atherosclerosis. We, therefore, investigated the role of C5aR2 in atherosclerosis and vascular remodelling. Here, we demonstrate that C5ar2 deletion, in atherosclerosis-prone mice, attenuates atherosclerotic as well as neointimal plaque formation, reduces macrophages and CD3+ T cells and induces features of plaque stability, as analysed by histomorphometry and quantitative immunohistochemistry. As a possible underlying mechanism, C5ar2-deficient plaques showed significantly reduced expression of C5a receptor (C5ar1), Tnf-α as well as Vcam-1, as determined by qPCR and quantitative immunohistochemistry. In addition, in vitro mechanistic studies revealed a reduction of these pro-inflammatory and pro-atherosclerotic mediators in C5ar2-deficient macrophages. Finally, blocking C5ar1 with antagonist JPE1375, in C5ar2^-/-/Apoe^-/- mice, led to a further reduction in neointimal plaque formation with reduced inflammation. In conclusion, C5ar2 deficiency attenuates atherosclerosis and neointimal plaque formation after arterial injury. This identifies C5aR2 as a promising target to reduce atherosclerosis and restenosis after vascular interventions.

The review process for this paper was fully handled by Gregory Y. H. Lip, Editor in Chief.

Keywords

Atherosclerosis - complement receptors - cytokines - vascular remodelling - gene knock-out

• References

• 1 Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
• 2 Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nature Med 2011; 17: 1410-1422.
• 3 Gerard C, Gerard NP. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol 1994; 12: 775-808.
• 4 Speidl WS, Kastl SP, Hutter R. et al. The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMP-1 and MMP-9 in human macrophages in vitro. FASEB J 2011; 25: 35-44.
• 5 Speidl WS, Katsaros KM, Kastl SP. et al. Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. Atherosclerosis 2010; 208: 285-289.
• 6 Li R, Coulthard LG, Wu MC. et al. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J 2013; 27: 855-864.
• 7 Klos A, Wende E, Wareham KJ. et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev 2013; 65: 500-543.
• 8 Laudes IJ, Chu JC, Huber-Lang M. et al. Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol 2002; 169: 5962-5970.
• 9 Monk PN, Scola AM, Madala P. et al. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 2007; 152: 429-448.
• 10 Shagdarsuren E, Bidzhekov K, Mause SF. et al. C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice. Circulation 2010; 122: 1026-1036.
• 11 Bamberg CE, Mackay CR, Lee H. et al. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem 2010; 285: 7633-7644.
• 12 Boor P, Konieczny A, Villa L. et al. Complement C5 mediates experimental tubulointerstitial fibrosis. J Am Soc Nephrol 2007; 18: 1508-1515.
• 13 Rittirsch D, Flierl MA, Nadeau BA. et al. Functional roles for C5a receptors in sepsis. Nature Med 2008; 14: 551-557.
• 14 Chen NJ, Mirtsos C, Suh D. et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 2007; 446: 203-207.
• 15 Scola AM, Johswich KO, Morgan BP. et al. The human complement fragment receptor, C5L2, is a recycling decoy receptor. Mol Immunol 2009; 46: 1149-1162.
• 16 Gerard NP, Lu B, Liu P, Craig S, Fujiwara Y, Okinaga S. et al. An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J Biol Chem 2005; 280: 39677-39680.
• 17 Vijayan S, Asare Y, Grommes J. et al. High expression of C5L2 correlates with high proinflammatory cytokine expression in advanced human atherosclerotic plaques. Am J Pathol 2014; 184: 2123-2133.
• 18 Doring Y, Soehnlein O, Drechsler M. et al. Hematopoietic interferon regulatory factor 8-deficiency accelerates atherosclerosis in mice. Arterioscl Thromb Vasc Biol 2012; 32: 1613-1623.
• 19 Schober A, Manka D, von Hundelshausen P. et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106: 1523-1529.
• 20 Schnatbaum K, Locardi E, Scharn D. et al. Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett 2006; 16: 5088-5092.
• 21 Shagdarsuren E, Bidzhekov K, Djalali-Talab Y. et al. C1-esterase inhibitor protects against neointima formation after arterial injury in atherosclerosis-prone mice. Circulation 2008; 117: 70-78.
• 22 Zernecke A, Bot I, Djalali-Talab Y. et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circulation Res 2008; 102: 209-217.
• 23 Liehn EA, Piccinini AM, Koenen RR. et al. A new monocyte chemotactic protein-1/chemokine CC motif ligand-2 competitor limiting neointima formation and myocardial ischemia/reperfusion injury in mice. J Am Coll Cardiol 2010; 56: 1847-1857.
• 24 Asare Y, Shagdarsuren E, Schmid JA. et al. Endothelial CSN5 impairs NF-kappaB activation and monocyte adhesion to endothelial cells and is highly expressed in human atherosclerotic lesions. Thromb Haemost 2013; 110: 141-152.
• 25 Paglialunga S, Schrauwen P, Roy C. et al. Reduced adipose tissue triglyceride synthesis and increased muscle fatty acid oxidation in C5L2 knockout mice. J Endocrinol 2007; 194: 293-304.
• 26 Inoue T, Croce K, Morooka T. et al. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interven 2011; 4: 1057-1066.
• 27 von Hundelshausen P, Weber C. Chronic inflammation and atherosclerosis. Deut Med Wochenschr 2013; 138: 1839-1844.
• 28 Colin S, Chinetti-Gbaguidi G, Staels B. Macrophage phenotypes in atherosclerosis. Immunol Rev 2014; 262: 153-166.
• 29 Gao H, Neff TA, Guo RF. et al. Evidence for a functional role of the second C5a receptor C5L2. FASEB J 2005; 19: 1003-1005.
• 30 Ohta H, Wada H, Niwa T. et al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005; 180: 11-17.
• 31 Cybulsky MI, Iiyama K, Li H. et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001; 107: 1255-1262.
• 32 Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscl Thromb Vasc Biol 2007; 27: 2292-2301.
• 33 Cuff CA, Kothapalli D, Azonobi I. et al. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest 2001; 108: 1031-1040.
• 34 Ramos CL, Huo Y, Jung U. et al. Direct demonstration of P-selectin- and VCAM-1-dependent mononuclear cell rolling in early atherosclerotic lesions of apolipoprotein E-deficient mice. Circ Res 1999; 84: 1237-1244.
• 35 Chow A, Huggins M, Ahmed J. et al. CD169(+) macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nature Med 2013; 19: 429-436.
• 36 Poursharifi P, Lapointe M, Petrin D. et al. C5L2 and C5aR interaction in adipocytes and macrophages: insights into adipoimmunology. Cell Signal 2012; 25: 910-918.
• 37 Croker DE, Halai R, Fairlie DP. et al. C5a, but not C5a-des Arg, induces upregulation of heteromer formation between complement C5a receptors C5aR and C5L2. Immunol Cell Biol 2013; 91: 625-633.
• 38 Manthey HD, Thomas AC, Shiels IA. et al. Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice. FASEB J 2011; 25: 2447-2455.
• 39 Cianflone K, Xia Z, Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 2003; 1609: 127-143.
• 40 Liu YAF, Lapointe M, Cianflone K. C5L2 Deficiency Enhances Development of Atherosclerosis in ApoE Knockout Mice. Chinese Med 2015; 6: 61-74.